This Jetrea market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the increasing incidence of vitreomacular traction (VMT), approval for the treatment of symptomatic vitreomacular adhesion, a growing aging population, the potential to reduce surgical interventions, and market exclusivity as an orphan drug.
Growth during the forecast period is expected to be driven by awareness and education initiatives, partnerships and licensing agreements, clinical efficacy demonstrated in trials, advancements in ophthalmic treatments, and regulatory support and approval. Key trends anticipated during the forecast period include technological advancements, increasing awareness of vitreomacular conditions, strategic partnerships for commercialization, a heightened focus on real-world evidence, and expanded market availability.
The increasing prevalence of retinal diseases is expected to drive the growth of the jetrea market in the future. Retinal diseases are a group of conditions that impact the retina, the light-sensitive tissue at the back of the eye, and can lead to vision loss or blindness if untreated. The rising prevalence of retinal diseases is influenced by aging populations, increasing rates of diabetes, and greater exposure to risk factors such as hypertension and lifestyle changes. Jetrea (ocriplasmin) is used to treat vitreomacular traction and macular holes, addressing retinal diseases linked to age-related and diabetic eye conditions. For example, in May 2024, The Royal College of Ophthalmologists reported that by 2050, the prevalence of sight loss and blindness caused by age-related macular degeneration (AMD) is expected to rise significantly, increasing from 23.1% to 29.7%. This growth indicates that the affected population will more than double, from approximately 445,809 individuals to an estimated 1.23 million. Therefore, the rising prevalence of retinal diseases is driving the jetrea market.
The growing number of clinical trials is anticipated to fuel the expansion of the jetrea market. Clinical trials are structured research studies conducted to assess the effectiveness, safety, and potential side effects of medical treatments, drugs, or devices in humans. The increasing number of clinical trials reflects the evolving complexity of healthcare needs, advancements in science, and the broadening scope of medical research. Jetrea, with its innovative mechanism for treating symptomatic vitreomacular adhesion (sVMA), supports clinical trials by providing a targeted therapeutic option, enhancing the evaluation of efficacy and safety for this condition, and advancing research in retinal health. For instance, in November 2023, the Association of the British Pharmaceutical Industry reported that the total number of industry-sponsored clinical trials initiated in the UK rose by 4.3%, increasing from 394 trials in 2021 to 411 in 2022. Thus, the growing number of clinical trials is driving the jetrea market.
The rise of personalized medicine is also expected to propel the growth of the jetrea market. Personalized medicine is a tailored healthcare approach that adjusts treatment strategies to the unique characteristics of each patient, including their genetic makeup, environment, and lifestyle, to achieve optimal outcomes. The growing focus on personalized medicine is driven by advancements in genomic technologies, an improved understanding of molecular biology, the increasing availability of precision diagnostic tools, and the demand for targeted therapies that enhance patient outcomes while reducing side effects. Personalized medicine aligns with Jetrea’s precise mechanism of action, which treats specific retinal conditions such as symptomatic vitreomacular adhesion (sVMA) by offering a non-surgical, individualized treatment option. For example, in 2023, the Personalized Medicine Coalition reported that 34% of the new drugs approved by the FDA in 2022 were personalized medicines, and for the previous eight years, personalized medicines accounted for at least 25% of new drug approvals. Therefore, the growing emphasis on personalized medicine is driving the jetrea market.
The key company in the jetrea market is Oxurion NV (Formerly ThromboGenics Inc.).
North America was the largest region in the Jetrea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in jetrea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the jetrea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Jetrea (ocriplasmin) is a pharmacologic agent used for the treatment of vitreomacular adhesion (VMA) and macular hole. It functions by enzymatically breaking down the proteins that cause abnormal adhesion between the vitreous body and the macula, a condition that can result in visual impairment.
The primary indications in the jetrea market include vitreomacular traction (VMT), symptomatic vitreomacular adhesion, and combination therapy. Vitreomacular traction occurs when the vitreous gel, which fills the interior of the eye, adheres abnormally to the macula, the central part of the retina responsible for sharp and detailed vision. The patient demographics include adult patients, elderly patients, and high-risk groups, with distribution channels such as direct sales, pharmaceutical wholesalers, online pharmacies, and international markets. The key end users include ophthalmologists, hospitals and clinics, outpatient surgical centers, and research institutions.
The jetrea market research report is one of a series of new reports that provides jetrea market statistics, including the jetrea industry global market size, regional shares, competitors with the jetrea market share, detailed jetrea market segments, market trends, and opportunities, and any further data you may need to thrive in the jetrea industry. This jetrea market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The jetrea market consists of sales of jetrea as single use intravitreal injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values are revenues generated by organizations in the specified geography within the market irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the increasing incidence of vitreomacular traction (VMT), approval for the treatment of symptomatic vitreomacular adhesion, a growing aging population, the potential to reduce surgical interventions, and market exclusivity as an orphan drug.
Growth during the forecast period is expected to be driven by awareness and education initiatives, partnerships and licensing agreements, clinical efficacy demonstrated in trials, advancements in ophthalmic treatments, and regulatory support and approval. Key trends anticipated during the forecast period include technological advancements, increasing awareness of vitreomacular conditions, strategic partnerships for commercialization, a heightened focus on real-world evidence, and expanded market availability.
The increasing prevalence of retinal diseases is expected to drive the growth of the jetrea market in the future. Retinal diseases are a group of conditions that impact the retina, the light-sensitive tissue at the back of the eye, and can lead to vision loss or blindness if untreated. The rising prevalence of retinal diseases is influenced by aging populations, increasing rates of diabetes, and greater exposure to risk factors such as hypertension and lifestyle changes. Jetrea (ocriplasmin) is used to treat vitreomacular traction and macular holes, addressing retinal diseases linked to age-related and diabetic eye conditions. For example, in May 2024, The Royal College of Ophthalmologists reported that by 2050, the prevalence of sight loss and blindness caused by age-related macular degeneration (AMD) is expected to rise significantly, increasing from 23.1% to 29.7%. This growth indicates that the affected population will more than double, from approximately 445,809 individuals to an estimated 1.23 million. Therefore, the rising prevalence of retinal diseases is driving the jetrea market.
The growing number of clinical trials is anticipated to fuel the expansion of the jetrea market. Clinical trials are structured research studies conducted to assess the effectiveness, safety, and potential side effects of medical treatments, drugs, or devices in humans. The increasing number of clinical trials reflects the evolving complexity of healthcare needs, advancements in science, and the broadening scope of medical research. Jetrea, with its innovative mechanism for treating symptomatic vitreomacular adhesion (sVMA), supports clinical trials by providing a targeted therapeutic option, enhancing the evaluation of efficacy and safety for this condition, and advancing research in retinal health. For instance, in November 2023, the Association of the British Pharmaceutical Industry reported that the total number of industry-sponsored clinical trials initiated in the UK rose by 4.3%, increasing from 394 trials in 2021 to 411 in 2022. Thus, the growing number of clinical trials is driving the jetrea market.
The rise of personalized medicine is also expected to propel the growth of the jetrea market. Personalized medicine is a tailored healthcare approach that adjusts treatment strategies to the unique characteristics of each patient, including their genetic makeup, environment, and lifestyle, to achieve optimal outcomes. The growing focus on personalized medicine is driven by advancements in genomic technologies, an improved understanding of molecular biology, the increasing availability of precision diagnostic tools, and the demand for targeted therapies that enhance patient outcomes while reducing side effects. Personalized medicine aligns with Jetrea’s precise mechanism of action, which treats specific retinal conditions such as symptomatic vitreomacular adhesion (sVMA) by offering a non-surgical, individualized treatment option. For example, in 2023, the Personalized Medicine Coalition reported that 34% of the new drugs approved by the FDA in 2022 were personalized medicines, and for the previous eight years, personalized medicines accounted for at least 25% of new drug approvals. Therefore, the growing emphasis on personalized medicine is driving the jetrea market.
The key company in the jetrea market is Oxurion NV (Formerly ThromboGenics Inc.).
North America was the largest region in the Jetrea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in jetrea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the jetrea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Jetrea (ocriplasmin) is a pharmacologic agent used for the treatment of vitreomacular adhesion (VMA) and macular hole. It functions by enzymatically breaking down the proteins that cause abnormal adhesion between the vitreous body and the macula, a condition that can result in visual impairment.
The primary indications in the jetrea market include vitreomacular traction (VMT), symptomatic vitreomacular adhesion, and combination therapy. Vitreomacular traction occurs when the vitreous gel, which fills the interior of the eye, adheres abnormally to the macula, the central part of the retina responsible for sharp and detailed vision. The patient demographics include adult patients, elderly patients, and high-risk groups, with distribution channels such as direct sales, pharmaceutical wholesalers, online pharmacies, and international markets. The key end users include ophthalmologists, hospitals and clinics, outpatient surgical centers, and research institutions.
The jetrea market research report is one of a series of new reports that provides jetrea market statistics, including the jetrea industry global market size, regional shares, competitors with the jetrea market share, detailed jetrea market segments, market trends, and opportunities, and any further data you may need to thrive in the jetrea industry. This jetrea market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The jetrea market consists of sales of jetrea as single use intravitreal injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values are revenues generated by organizations in the specified geography within the market irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Jetrea Market Characteristics4. Jetrea Market Trends and Strategies5. Jetrea Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Jetrea Pricing Analysis & Forecasts30. Global Jetrea Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Jetrea Market32. Recent Developments in the Jetrea Market
3. Jetrea Market Biologic Drug Characteristics
6. Global Jetrea Growth Analysis and Strategic Analysis Framework
8. Jetrea Market Segmentation
9. Global Jetrea Epidemiology of Clinical Indications
10. Jetrea Market Regional and Country Analysis
11. Asia-Pacific Jetrea Market
12. China Jetrea Market
13. India Jetrea Market
14. Japan Jetrea Market
15. Australia Jetrea Market
16. South Korea Jetrea Market
17. Western Europe Jetrea Market
18. UK Jetrea Market
19. Germany Jetrea Market
20. France Jetrea Market
21. Eastern Europe Jetrea Market
22. North America Jetrea Market
23. USA Jetrea Market
24. Canada Jetrea Market
25. South America Jetrea Market
26. Middle East Jetrea Market
27. Africa Jetrea Market
28. Jetrea Market Competitive Landscape and Company Profiles
29. Global Jetrea Market Pipeline Analysis
33. Jetrea Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Jetrea Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on jetrea market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for jetrea? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The jetrea market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Vitreomacular Traction; Symptomatoc Vitreomacular Adhesion; Combination Therapy2) by Patient Demographics: Adult Patients; Elderly Patients; High-Risk Groups
3) by Distribution Channel: Direct Sales; Pharmaceutical Wholesalers; Online Pharmacies; International Markets
4) by End User: Ophthalmologists; Hospitals and Clinics; Outpatient Surgical Centres; Research Institutions
Key Companies Mentioned: Oxurion NV (Formerly ThromboGenics Inc.)
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Oxurion NV (Formerly ThromboGenics Inc.)
